Yüklüyor......
BAFF inhibition in SLE – is tolerance restored?
The B cell activating factor (BAFF) inhibitor, belimumab, is the first biologic drug approved for the treatment of SLE, and exhibits modest, but durable, efficacy in decreasing disease flares and organ damage. BAFF and its homolog APRIL are TNF-like cytokines that support the survival and differenti...
Kaydedildi:
| Yayımlandı: | Immunol Rev |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6935406/ https://ncbi.nlm.nih.gov/pubmed/31562657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/imr.12810 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|